Kymera Therapeutics Inc. (NASDAQ: KYMR) presented preclinical data for KT-579, its oral IRF5 degrader drug candidate, at medical conferences in June. The company reported that KT-579 demonstrated disease-modifying activity in multiple preclinical lupus models with results comparable or superior to approved therapies.

The data were presented at the European Alliance of Associations for Rheumatology Annual Meeting in London and the Federation of Clinical Immunology Societies Annual Meeting in San Francisco. KT-579 is designed as a first-in-class oral degrader that targets IRF5, a transcription factor involved in immune regulation.

In preclinical studies using human cells from healthy donors and lupus patients, KT-579 selectively degraded IRF5 and reduced inflammatory mediators including Type I interferons and pro-inflammatory cytokines. The compound also decreased plasmablast differentiation and antibody production. In animal models, KT-579 showed dose-dependent IRF5 degradation and inhibition of cytokine release.

Across multiple lupus models, KT-579 treatment reduced disease biomarkers including proteinuria, serum autoantibodies and kidney pathology. The company stated the results were comparable or superior to approved and clinically active agents tested in the same models.

Kymera is currently conducting a Phase 1 healthy volunteer trial evaluating KT-579's safety, tolerability and pharmacokinetics. The study aims to demonstrate that KT-579 can degrade IRF5 in blood at safe and well-tolerated doses. The company expects to report data from this trial in the second half of 2026.

Following the healthy volunteer study, Kymera plans to initiate a patient proof-of-concept trial, likely in lupus patients. The company describes KT-579 as having potential applications in multiple autoimmune diseases including lupus, rheumatoid arthritis and inflammatory bowel disease.